Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.

Cui Y, Zong H, Yang C, Yan H, Zhang Y.

Int Urol Nephrol. 2013 Aug;45(4):979-87. doi: 10.1007/s11255-013-0477-0. Epub 2013 Jun 1. Review.

PMID:
23728850
[PubMed - indexed for MEDLINE]
2.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.

J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026. Epub 2011 May 14.

PMID:
21575967
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis.

Cui Y, Zhang Y.

Eur Urol. 2013 Nov;64(5):811-22. doi: 10.1016/j.eururo.2013.03.042. Epub 2013 Apr 3. Review.

PMID:
23567065
[PubMed - indexed for MEDLINE]
4.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
[PubMed - indexed for MEDLINE]
5.

The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Zhang Y.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):132-43. doi: 10.1038/pcan.2013.60. Epub 2014 Jan 21.

PMID:
24445948
[PubMed - in process]
6.

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S.

JAMA. 2012 Mar 7;307(9):931-9. doi: 10.1001/jama.2012.227.

PMID:
22396515
[PubMed - indexed for MEDLINE]
7.

Effects of androgen deficiency and replacement on prostate zonal volumes.

Jin B, Conway AJ, Handelsman DJ.

Clin Endocrinol (Oxf). 2001 Apr;54(4):437-45.

PMID:
11318778
[PubMed - indexed for MEDLINE]
8.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

Eur Urol. 2000 Apr;37(4):367-80. Review.

PMID:
10765065
[PubMed - indexed for MEDLINE]
9.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

World J Urol. 2002 Apr;19(6):413-25. Review.

PMID:
12022710
[PubMed - indexed for MEDLINE]
10.

Benign prostatic hyperplasia progression and its impact on treatment.

Djavan B, Waldert M, Ghawidel C, Marberger M.

Curr Opin Urol. 2004 Jan;14(1):45-50. Review.

PMID:
15091050
[PubMed - indexed for MEDLINE]
11.
12.

Finasteride for benign prostatic hyperplasia.

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review.

PMID:
20927745
[PubMed - indexed for MEDLINE]
13.

Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.

Helfand BT, Blackwell RH, McVary KT.

J Urol. 2010 Jul;184(1):218-23. doi: 10.1016/j.juro.2010.03.020. Epub 2010 May 16.

PMID:
20483154
[PubMed - indexed for MEDLINE]
14.

Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.

Habib FK, Ross M, Tate R, Chisholm GD.

Clin Endocrinol (Oxf). 1997 Feb;46(2):137-44.

PMID:
9135694
[PubMed - indexed for MEDLINE]
15.

Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.

Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42. doi: 10.1152/ajpendo.00592.2013. Epub 2013 Dec 10.

PMID:
24326421
[PubMed - indexed for MEDLINE]
16.

5alpha-reductase inhibitors: what role should they play?

Kaplan SA.

Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70. Review.

PMID:
11750255
[PubMed - indexed for MEDLINE]
17.

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.

Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J.

J Urol. 2013 Aug;190(2):615-9. doi: 10.1016/j.juro.2013.03.024. Epub 2013 Mar 14.

PMID:
23499746
[PubMed - indexed for MEDLINE]
18.
19.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
[PubMed - indexed for MEDLINE]
20.

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ.

BJU Int. 2012 Jun;109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x. Epub 2012 May 2. Review.

PMID:
22551330
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk